Peptide Initiative

Peptides · Peptide comparison

Larazotide vs TB-500

Restore your intestinal barrier and protect against gluten damage

A powerful fragment of thymosin beta-4 that acts like your body's repair signal—speeding up healing of muscles, tendons, and tissues by promoting cell migration and new blood vessel growth right where you need it most.

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeLarazotide0.5–0.5 mgTB-5002–2.5 mg
FrequencyLarazotideOnce dailyTB-500Twice weekly
AdministrationLarazotideOral (capsule or tablet)TB-500Subcutaneous injection
Cycle lengthLarazotideOngoing/indefiniteTB-5004-6 weeks
Onset speedLarazotideModerate (1-2 weeks)TB-500Moderate (1-2 weeks)
Evidence levelLarazotideStrong human trials (Phase 3 or FDA approved)TB-500Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Intestinal Barrier Protection

Larazotide95%
TB-500No recorded rating

Celiac Disease Management

Larazotide85%
TB-500No recorded rating

Safety & Tolerability

Larazotide90%
TB-500No recorded rating

Healing Speed

LarazotideNo recorded rating
TB-50095%

Tissue Repair

LarazotideNo recorded rating
TB-50093%

Anti-Scarring

LarazotideNo recorded rating
TB-50088%

Technical data

Compound specifications

Larazotide

Molecular formula
C34H59N9O12
Molecular weight
785.9 g/mol
Half-life
Unknown - acts primarily as local intestinal barrier regulator rather than systemic drug
Bioavailability
Orally administered; acts locally on intestinal epithelium with minimal systemic absorption
CAS number
206899-25-6

TB-500

Molecular formula
C38H68N10O14
Molecular weight
889.01 g/mol
Half-life
2-3 days (systemic)
Bioavailability
High via subcutaneous injection (~100%)
CAS number
885340-08-9

Protocols

Dosing compared

Larazotide

Oral

  • 0.5 mgThree times daily (before meals) · 12 weeks in trials; ongoing for symptom controlTrial-established dose: in a Phase 2b randomized controlled trial in celiac disease, 0.5 mg three times daily met the primary endpoint with fewer symptoms vs placebo. Notably, the higher 1 mg and 2 mg doses showed no benefit over placebo, so 0.5 mg is the effective dose [6]. Taken before meals as a local intestinal tight-junction regulator [1].

TB-500

Subcutaneous

  • 2-2.5 mgTwice weekly · Loading phase, 4-6 weeksResearch peptide with no human trials of the fragment; [9] loading doses used in practice [6].
  • 2-2.5 mgOnce weekly · Maintenance after loadingMaintenance dose used in practice following the loading phase [6].

Applications

Best suited for

Larazotide

Managing celiac disease symptoms despite strict gluten avoidance
Larazotide is particularly well-suited for individuals focused on managing celiac disease symptoms despite strict gluten avoidance. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
Reducing accidental gluten exposure damage
Larazotide is particularly well-suited for individuals focused on reducing accidental gluten exposure damage. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring digestive comfort and nutrient absorption
Larazotide is particularly well-suited for individuals focused on restoring digestive comfort and nutrient absorption. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting intestinal healing and barrier function
Larazotide is particularly well-suited for individuals focused on supporting intestinal healing and barrier function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

TB-500

Athletes Recovering from Muscle Injuries
If you've pulled a hamstring, strained your back, or torn a muscle, TB-500 helps accelerate the healing process by promoting cell migration to the injury site and supporting new blood vessel growth. It's especially useful for injuries that just won't seem to fully heal [1][5].
Tendon and Ligament Problems
Tendons and ligaments are notoriously slow healers because they have poor blood supply. TB-500 promotes angiogenesis (new blood vessel formation) and helps repair these stubborn connective tissue injuries—think Achilles tendonitis, tennis elbow, or rotator cuff issues [5].
Post-Surgical Recovery
After surgery, your body needs to repair a lot of tissue quickly. TB-500 supports wound healing, reduces inflammation, and may help minimize scar tissue formation. Some protocols use it alongside traditional recovery to potentially speed up the healing timeline [1][4].
Chronic Inflammation and Slow Healers
Some people just heal slowly—whether due to age, diabetes, or other factors. TB-500 helps regulate the inflammatory response and promotes the cellular processes needed for tissue repair. It essentially tells your body to focus healing resources where they're needed most [1].

Safety profile

Side effects

Larazotide

Common

  • Nausea
  • Abdominal Cramping
  • Fatigue

Uncommon

  • Transient Diarrhea

Serious

  • Allergic Reaction

TB-500

Common

  • Injection site redness
  • Mild fatigue or lethargy
  • Mild headache
  • Slight flushing

Uncommon

  • Head rush or lightheadedness
  • Temporary nausea

Serious

  • Allergic reaction

Research status

Safety & evidence

Larazotide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Not FDA approved
Safety overview
Larazotide (AT-1001) is a synthetic tight-junction regulator. In Phase 2 celiac disease trials it reduced symptoms at the 0.5 mg dose, but a pooled analysis found no improvement in intestinal permeability versus placebo; safety was comparable to placebo [1][6]. The mechanism—zonula occludens-1 modulation—is specific to epithelial tight junctions without broad immunosuppression. Gastrointestinal side effects (nausea, diarrhea, abdominal pain) occur in 10-20% of patients but are typically mild and resolve with dose adjustment or continued exposure. FDA feedback on Phase 3 trials indicated efficacy trends but required additional manufacturing and clinical data before approval consideration.

Contraindications

  • Known hypersensitivity to larazotide or any component
  • Severe gastrointestinal obstruction
  • Active untreated infections (may require monitoring)
  • Pregnancy and breastfeeding (limited safety data)

TB-500

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
TB-500 has shown a good safety profile across preclinical studies and limited human research. It's a fragment of thymosin beta-4, a naturally occurring protein in your body involved in healing. Most side effects are mild and transient, primarily injection site reactions. However, large-scale clinical trials are still needed to fully establish its safety profile in humans [1].

Contraindications

  • Pregnancy or planning to become pregnant
  • Currently breastfeeding
  • Active cancer or history of cancer
  • Known allergy to peptide components
  • Children and adolescents

Decision guide

Which is right for you?

Larazotide

Choose Larazotide if…

  • Managing celiac disease symptoms despite strict gluten avoidance
  • Reducing accidental gluten exposure damage
  • Restoring digestive comfort and nutrient absorption
  • Supporting intestinal healing and barrier function

TB-500

Choose TB-500 if…

  • Accelerating injury recovery
  • Tendon and ligament healing
  • Reducing chronic inflammation
  • Post-surgical recovery support